Background: Optimal imaging for children with pediatric malignant melanoma (MM) is unknown.
INTRODUCTION
Cutaneous malignant melanoma (MM) in children and adolescents is rare with most cases affecting patients between 15 and 19 years of age. 1 Genomic and pathologic analysis has identified three distinct subgroups of lesions that are associated with markedly different risks for treatment failure: de novo conventional melanoma (CM), melanoma arising in a congenital melanocytic nevus, and spitzoid melanoma. 2 The optimal imaging approach to diagnose and follow pediatric patients with MM has not been well established, therefore, guidelines Abbreviations: CM, conventional melanoma; CT, computed tomography; CTCAP, CT chest, abdomen, and pelvis; MM, malignant melanoma; MRI, magnetic resonance imaging; PET/CT, positron emission tomography/computed tomography; SLN, sentinel lymph node; TERT, telomerase reverse transcriptase for adults are usually followed regardless of the histologic or genomic subtype. The use of imaging modalities such as computed tomography (CT) modalities is costly and associated with risks such as radiation exposure, and complications related to anesthesia.
To better define the role of imaging in children and adolescents with MM, we reviewed our experience at St. Jude Children's Research Hospital in children who were uniformly treated on an institutional melanoma trial.
PATIENTS AND METHODS
We retrospectively reviewed the medical records of patients aged The diagnosis of melanoma in all cases was centrally reviewed and additional genomic tests such as fluorescence in situ hybridization, comparative genomic hybridization, and mutational analysis were performed to define the subtype of melanoma. The specific criteria for the diagnosis of spitzoid melanoma have been summarized previously. 4 Telomerase reverse transcriptase (TERT) promoter mutational analysis was performed retrospectively in all patients with spitzoid melanoma.
Imaging findings were considered suspicious for disease if the interpreting physician reported persistent abnormal findings through more than one imaging modality leading to further clinical/radiological follow-up, tissue biopsy, and/or evaluation by another imaging modality. Imaging findings and number were collected until the time of first event, defined as disease recurrence, progression, or death. Cost of each scan includes the technical charge and the professional fee; the cost of anesthesia was excluded.
Effective doses for common radiation-based imaging exams at our institution were recently published for five age groups. 5 Dose estimates were derived using updated age-averaged and gender-averaged tissue-weighting factors provided in Report 103 by the International Committee on Radiological Protection and are currently used by our Institutional Review Board as a reference for reviewing research protocols. To provide a general estimate of radiation dose burden for each patient in this study, effective dose from a particular imaging examination type (eg, head CT, chest CT, fluordeoxyglucose-PET, etc.) was assigned using this reference and the age of the subject at the time of enrollment. Cumulative effective dose was then approximated for each patient by summing up dose values for protocol-related imaging as well as additional imaging performed due to abnormal findings.
The decision to obtain tissue for histologic analysis was left to the discretion of the treating physician.
RESULTS

Patient characteristics
From June 2007 through September 2012, we identified 21 patients (11 females) meeting eligibility criteria. The median age was 14 years (range, 3.2-22.1). Ten patients had CM and 11 patients had spitzoid melanoma (Table 1) . Primary sites were head and neck (n = 6), trunk (n = 7), and extremities (n = 8). Sixteen patients were treated on stratum A, two on stratum B1, and three on stratum B2. A total of 398 imaging studies (147 PET/CT, 138 CTCAP, 19 CT chest, 17 CT brain, and MRI brain) were performed with a median of 8, 7, 0, 1, and 3 studies per patient, over an average of 35 months of follow-up, respectively. The total cost for all the imaging studies performed in these patients is estimated to be $577,952.00. The average and median cumulative effective doses of imaging-based radiation across patients were 108.8 mSv (range 32.5-198.5 mSv) and 107 mSv, respectively. which led to an additional 28 studies and two biopsies. One of the two lung biopsies in two patients was positive for disease and the other showed granuloma. The remaining abnormalities (n = 11) either remained stable (n = 4), regressed (n = 4), or were thought to be due to benign based on radiographic appearance and therefore no biopsy was obtained (n = 3, intussusception, thyroid cyst, nonossifying fibroma).
Analysis
Of the 13 suspicious scans performed on 10 patients, only one had an abnormality that was attributed to disease; this was detected 12 months after diagnosis. This patient died of disease 18 months after diagnosis, whereas the remaining patients were in the first remission 4.9-9.2 years after diagnosis. In retrospect, only one had a documented TERT promoter mutation.
Characteristics of suspicious scans and outcomes
At diagnosis
Four CT scans of the chest were positive: one patient had a lung nodule measuring 0.9 cm × 1.1 cm that slightly increased and became more dense over 2 weeks-confirmed by biopsy to be a granuloma. CT scans in two other patients showed nodules that initially measured <5 mm and repeat scan 2 weeks later were interpreted to be suspicious for infection in one and stable in the other. Scan in the fourth patient showed a 3-mm nodule that regressed in a follow-up scan 1 week later.
During therapy
Five scans were suspicious for disease: one showed multiple pulmonary nodules (largest 6 mm in diameter) that progressed on followup scans, and confirmed on biopsy to be metastatic disease. One PET/CT scan in another patient showed a metabolically avid lesion in the femoral head 9 months after diagnosis, which on X-ray and MRI of the femur was typical of a nonossifying fibroma (Figure 2) . In a third case, PET/CT and CT of the abdomen showed enlargement of an abdominal lymph node (largest 2.3 cm × 0.9 cm) with moderately elevated uptake, which remained stable in follow-up scans. In the fourth patient, a sphenoid lucency on CT of the brain was negative on PET/CT and regressed on a follow-up scan. The last scan was an MRI of the brain that showed leptomeningeal enhancement suspicious for metastasis, which remained stable on multiple subsequent scans and in retrospect was a vascular anomaly. 
Off-therapy follow-up
Four scans had findings suspicious for disease: one CT chest showed new small lung nodules that remained stable on a follow-up scan after 3 months. In one patient, a PET/CT scan showed avidity in the thyroid gland, which was found on follow-up thyroid ultrasound (US) to be a benign thyroid cyst. CT and PET/CT in another patient showed an abdominal mass detected by CT and PET/CT, which proved by US to be an intussusception. PET/CT scan in the fourth patient showed a metabolically active enlarged cervical lymph node larger than 1 cm, clinically palpable and tender. It regressed on a follow-up scan 4 weeks later.
Conventional melanoma
The median age was 17.1 years (range, 3.9-22.1 years). Six patients were treated on stratum A, two on stratum B1, and two on stratum either remained stable (n = 7), regressed (n = 3), markedly progressed (n = 3), or was of benign etiology (n = 1, benign ovarian cyst). In total, 7 of the 20 scans showed true disease, of which five scans were from three patients who died of disease. The other two scans were from two patients who are alive and in the second complete remission, both at 6.3 years of follow-up. The rest of the patients were in the first complete remission 6.1-7.6 years after diagnosis.
Characteristics of suspicious scans and outcomes
At diagnosis
Seven scans had abnormal findings: Chest CT showed lung nodules/hilar abnormalities in three patients; one showed multiple lung nodules (largest 0.5 cm) and biopsy showed intraparenchymal lymph node. This patient developed locoregional recurrence 9 months after diagnosis but was disease-free at the last follow-up, 6.3 years after diagnosis. The other two scans showed a 0.3 cm lung nodule and a 0.9 cm hilar lymph node (slightly avid by PET/CT), respectively. Both remained stable over follow-up scans. A benign ovarian cyst was seen in one patient. In two other scans, recurrence was presumed at presentation for study enrollment, both had confirmatory biopsies. The last scan showed multiple metastatic sites that progressed later.
During therapy
Seven scans showed abnormalities: mediastinal lymph node enlargement in one patient who remained stable in two follow-up scans showed enhancement in the superficial tissues overlying the superior frontoparietal region. Clinical examination revealed a skin pustule that regressed on a follow-up scan. Locoregional enhancement was detected in three scans: in one, the patient felt a mass at the site of the primary tumor in the scalp. PET/CT and CT scans showed a 7 mm enhancing nodule that was confirmed to be recurrent disease by tissue biopsy. The second scan was a PET/CT scan that showed a 1.8 cm cervical lymph node with mild avidity. He was scheduled to undergo a follow-up scan 4 weeks after completing a course of antibiotics, but presented with clinically enlarging lymph node before that time.
Biopsy confirmed disease recurrence. The last scan was a brain MRI that showed mild enhancement in the cervical area with no discreet mass. The patient had a soft tissue swelling that was improving at the same time. Follow-up 6 weeks later showed stable scan. The last two scans showed marked progression of metastatic disease in two patients, each of whom had a wide spread metastatic disease at diagnosis.
Off-therapy follow-up
Six scans showed abnormalities concerning for disease recurrence:
a CT chest showed a 0.15 cm lung nodule that remained stable in the follow-up scan. Locoregional enhancement was seen by PET/CT in two patients. In the first case, the size of the lymph node was normal. Though it remained of normal size, metabolic avidity shown by PET/CT increased at follow-up. Biopsy showed benign lymphoid hyperplasia. In the other patient, the lymph node size was also normal and remained stable on a short follow-up scan. In the fourth case, metabolic activity shown on PET/CT scan increased activity in the high left parietal bone. The activity was attributed to normal brain activity and regressed on a follow-up PET/CT scan 3 months later. CT scan showed enlarged mesenteric lymph nodes (largest 1.7 cm) in a fifth case which remained stable 3 months later. The last scan was a PET/CT scan that showed increased metabolic activity in the subcarinal soft tissue without definitive CT demonstrable abnormality. This finding was thought to be brown fat. A repeat study performed 3 months later with diazepam pretreatment showed no metabolic activity. For surveillance for recurrence in patients with no evidence of disease, imaging is recommended at "3-12 months interval." There is debate on whether close follow-up in adult patients with melanoma is necessary. [6] [7] [8] [9] In a previous study at our center, imaging identified clinically undetectable metastases in 25% of patients with MM (8 out of 33 patients), all had thick lesions (Clark's level IV or V) or unknown primary sites.
Events and outcome
Based on those findings, we recommended CT of the chest, abdomen, and local-regional nodal basins at diagnosis to determine disease extent on all patients. 10 (≥4 mm Breslow thickness) and macrometastasis on SLN biopsy. 12 Two recent abstracts suggest that the yield of chest radiographs for surveillance after therapy for melanoma is low and PET may more accurately assess the long-term benefits of immunotherapy in these patients. 13, 14 US is highly sensitive and specific in evaluating regional lymph nodes in melanoma at diagnosis when compared to CT scan, PET scan, and combined PET/CT, while for distant metastases, PET/CT had the highest sensitivity and specificity. [15] [16] [17] In a prospective study of 211 adults with melanoma, Francken et al found that 73% of first melanoma recurrences were detected by the patient or their partner. 6 This was also seen in other studies. 9, [18] [19] [20] [21] In our cohort, two of three recurrences were detected clinically by the patient before or shortly after an abnormal scan, both were locoregional. Based on these findings, selfexamination and US may replace CT scan for disease follow-up, both of which are associated with less cost, no radiation exposure, and a high detection rate.
Spitzoid melanoma presents at a younger age, and despite a high incidence of nodal metastasis, survival approaches 100%. [22] [23] [24] In our cohort, the median age of diagnosis in patients with spitzoid melanoma was 8.4 years compared to 17.1 year in patients with CM, similar to other reports. 25 Studies at our institution have identified alterations in the TERT promoter that are linked to an aggressive behavior in spitzoid melanoma. 4 In our current series, the only patient with spitzoid melanoma with metastasis tested positive for a TERT promoter mutation.
The average 5-year survival rate for patients with metastatic CM is less than 10%. 26, 27 Several new targeted and immune therapies have shown antitumor activity with acceptable side effects in patients with advanced melanoma. [28] [29] [30] Number and site of metastasis are among several factors that influence survival in patients with metastatic melanoma 27 suggesting that close follow-up imaging of patients with CM to detect low disease burden and at an early stage, coupled with new immune therapies may prolong survival for patients with high-risk disease.
Baseline and follow-up imaging expose patients to ionizing radiation, and can result in high cumulative effective doses of radiation. 31 A number of reports have shown that CT scans during childhood and adolescence may be associated with an increase in future cancer risk. [32] [33] [34] In this study, patients received an average of 108. 35, 36 Sedations for MRI in children have also been associated with reduced cerebral blood flow and increased cerebral blood volume, 37 and repeated procedural sedation with general anesthesia may decrease neurocognitive outcomes in selected pediatric patients. 38 Another drawback of routine imaging is the detection of incidental findings that lead to unnecessary evaluations. 39 Finally, cost is an important factor to consider given the high cost of health care, 39 therefore the potential benefits of surveillance must be balanced with the cost and risks of routine surveillance imaging. Mooney et al reported that screening for asymptomatic pulmonary metastasis in patients with melanoma accounted for approximately 80% of the program costs. 40 Similarly, Meyers et al reported that more than $100,000 was spent on 20 patients to find only one recurrence that could not be detected or suspected by other means. 18 In our cohort, more than $500,000 was spent on scans to detect recurrent or progressive disease in six patients. Of these six patients, we identified one patient (spitzoid melanoma) with asymptomatic disease in whom imaging detected metastatic disease; the remaining five patients had CM who either had clinically detected mass at time of recurrence (n = 2) or wide spread disease at diagnosis (n = 3).
Although our study has a unified imaging protocol for all patients, it has some limitations-the small sample size and the retrospective analysis. These finding should be investigated in a larger cohort of patients.
In conclusion, we report herein a comparison between imaging findings for spitzoid melanoma and CM in pediatric patients.
Our results suggest that children and adolescents with spitzoid melanoma lacking TERT promoter alterations require minimal imaging at diagnosis and follow-up given their low risk of recurrence and the high cost and potential risks associated with advanced imaging studies. Patients with CM and spitzoid with TERT promoter alteration should be imaged according to the adult guidelines.
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